外泌体-miRNAs在骨肉瘤细胞耐药中发挥的作用机制
Mechanism of Exosome-miRNAs in Osteosarcoma Cells Drug Resistace
DOI: 10.12677/acm.2025.151108, PDF,   
作者: 王 岩*, 白 锐#：内蒙古医科大学第二附属医院儿童骨科，内蒙古 呼和浩特
关键词: 骨肉瘤；外泌体；耐药性；Osteosarcoma； Exosome； Drug Resistance
摘要: 骨肉瘤(OS)是最常见的原发性骨恶性肿瘤，其具备较高的局部侵袭、肺部转移率和病死率，常见于儿童、青少年，其次是老年人，目前针对骨肉瘤的主流治疗方式即手术切除并化疗，但该疾病治疗后转移进展和复发风险很高，其中的一个主要原因是化疗过程中骨肉瘤产生了对化疗药物的耐药性，肿瘤细胞产生耐药性是多水平、多因素、多基因机制引起的，其中外泌体-miRNAs机制是近些年在研究肿瘤耐药过程中所发现的一种机制，外泌体本质是一种双层脂质胞外囊泡，其可以参与细胞间的信息交流和物质传递，从而对骨肉瘤的耐药性造成影响。本文对当前较主流的外泌体在骨肉瘤耐药性产生中所起的作用机制进行了综述。
Abstract: Osteosarcoma (OS) is the most common primary bone malignant tumor, which has a high local invasion, lung metastasis rate and mortality rate. It is common in children and adolescents, followed by the elderly. The mainstream treatment for osteosarcoma is surgical resection and chemotherapy. However, the risk of metastatic progression and recurrence after treatment of this disease is very high. One of the main reasons is that osteosarcoma develops resistance to chemotherapeutic drugs during chemotherapy. The drug resistance of tumor cells is caused by multi-level, multi-factor, and multi-gene mechanisms. Among them, the mechanism of exosome-miRNAs is a mechanism discovered in the process of studying tumor drug resistance in recent years. The essence of exosomes is a bilayer lipid extracellular vesicle, which can participate in information exchange and material transmission between cells, thus affecting the drug resistance of osteosarcoma. This article reviews the mechanisms by which exosomes, currently one of the mainstream factors, contribute to the development of drug resistance in osteosarcoma.
文章引用：王岩, 白锐. 外泌体-miRNAs在骨肉瘤细胞耐药中发挥的作用机制[J]. 临床医学进展, 2025, 15(1): 805-811. https://doi.org/10.12677/acm.2025.151108

参考文献

[1] Hmada, Y.A., Bernieh, A., Morris, R.W., Lewin, J. and Allen, T. (2019) Chondroblastoma-Like Osteosarcoma. Archives of Pathology & Laboratory Medicine, 144, 15-17. [Google Scholar] [CrossRef] [PubMed]
[2] Anninga, J.K., Gelderblom, H., Fiocco, M., Kroep, J.R., Taminiau, A.H.M., Hogendoorn, P.C.W., et al. (2011) Chemotherapeutic Adjuvant Treatment for Osteosarcoma: Where Do We Stand? European Journal of Cancer, 47, 2431-2445. [Google Scholar] [CrossRef] [PubMed]
[3] Ritter, J. and Bielack, S.S. (2010) Osteosarcoma. Annals of Oncology, 21, vii320-vii325. [Google Scholar] [CrossRef] [PubMed]
[4] Song, X.J., Bi, M.C., Zhu, Q.S. and Liu, X.L. (2022) The Emerging Role of lncRNAs in the Regulation of Osteosarcoma Stem Cells. European Review for Medical and Pharmacological Sciences, 26, 966-974. [Google Scholar] [CrossRef] [PubMed]
[5] Li, B., Cao, Y., Sun, M. and Feng, H. (2021) Expression, Regulation, and Function of Exosome‐Derived miRNAs in Cancer Progression and Therapy. The FASEB Journal, 35, e21916. [Google Scholar] [CrossRef] [PubMed]
[6] Johnstone, R.M., Adam, M., Hammond, J.R., Orr, L. and Turbide, C. (1987) Vesicle Formation during Reticulocyte Maturation. Association of Plasma Membrane Activities with Released Vesicles (Exosomes). Journal of Biological Chemistry, 262, 9412-9420. [Google Scholar] [CrossRef] [PubMed]
[7] Yue, B., Yang, H., Wang, J., Ru, W., Wu, J., Huang, Y., et al. (2020) Exosome Biogenesis, Secretion and Function of Exosomal miRNAs in Skeletal Muscle Myogenesis. Cell Proliferation, 53, e12857. [Google Scholar] [CrossRef] [PubMed]
[8] 曾昭穆, 温稀超, 张雨豪, 等. 外泌体介导miRNAs在脑胶质瘤治疗中的作用与应用[J]. 中国组织工程研究, 2020, 24(25): 4073-4080.
[9] Pegtel, D.M. and Gould, S.J. (2019) Exosomes. Annual Review of Biochemistry, 88, 487-514. [Google Scholar] [CrossRef] [PubMed]
[10] Han, Q., Li, W., Hu, K., Gao, J., Zhai, W., Yang, J., et al. (2022) Exosome Biogenesis: Machinery, Regulation, and Therapeutic Implications in Cancer. Molecular Cancer, 21, Article No. 207. [Google Scholar] [CrossRef] [PubMed]
[11] Kalluri, R. (2016) The Biology and Function of Exosomes in Cancer. Journal of Clinical Investigation, 126, 1208-1215. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J. and Guo, W. (2021) Immunotherapy for Osteosarcoma: Fundamental Mechanism, Rationale, and Recent Breakthroughs. Cancer Letters, 500, 1-10. [Google Scholar] [CrossRef] [PubMed]
[13] Assil, S., Webster, B. and Dreux, M. (2015) Regulation of the Host Antiviral State by Intercellular Communications. Viruses, 7, 4707-4733. [Google Scholar] [CrossRef] [PubMed]
[14] Isaac, R., Reis, F.C.G., Ying, W. and Olefsky, J.M. (2021) Exosomes as Mediators of Intercellular Crosstalk in Metabolism. Cell Metabolism, 33, 1744-1762. [Google Scholar] [CrossRef] [PubMed]
[15] Hill, M. and Tran, N. (2021) MiRNA Interplay: Mechanisms and Consequences in Cancer. Disease Models & Mechanisms, 14, dmm047662. [Google Scholar] [CrossRef] [PubMed]
[16] Zuntini, M., Salvatore, M., Pedrini, E., Parra, A., Sgariglia, F., Magrelli, A., et al. (2010) MicroRNA Profiling of Multiple Osteochondromas: Identification of Disease‐Specific and Normal Cartilage Signatures. Clinical Genetics, 78, 507-516. [Google Scholar] [CrossRef] [PubMed]
[17] Naseri, M., Bozorgmehr, M., Zöller, M., Ranaei Pirmardan, E. and Madjd, Z. (2020) Tumor-Derived Exosomes: The Next Generation of Promising Cell-Free Vaccines in Cancer Immunotherapy. OncoImmunology, 9, Article 1779991. [Google Scholar] [CrossRef] [PubMed]
[18] Hosseinikhah, S.M., Gheybi, F., Moosavian, S.A., Shahbazi, M., Jaafari, M.R., Sillanpää, M., et al. (2022) Role of Exosomes in Tumour Growth, Chemoresistance and Immunity: State-of-the-Art. Journal of Drug Targeting, 31, 32-50. [Google Scholar] [CrossRef] [PubMed]
[19] Wu, Z., Yin, H., Liu, T., Yan, W., Li, Z., Chen, J., et al. (2014) MiR-126-5p Regulates Osteoclast Differentiation and Bone Resorption in Giant Cell Tumor through Inhibition of MMP-13. Biochemical and Biophysical Research Communications, 443, 944-949. [Google Scholar] [CrossRef] [PubMed]
[20] Lin, W., Fang, J., Wei, S., He, G., Liu, J., Li, X., et al. (2023) Extracellular Vesicle-Cell Adhesion Molecules in Tumours: Biofunctions and Clinical Applications. Cell Communication and Signaling, 21, Article No. 246. [Google Scholar] [CrossRef] [PubMed]
[21] Maleki, M., Golchin, A., Javadi, S., Khelghati, N., Morovat, P., Asemi, Z., et al. (2021) Role of Exosomal miRNA in Chemotherapy Resistance of Colorectal Cancer: A Systematic Review. Chemical Biology & Drug Design, 101, 1096-1112. [Google Scholar] [CrossRef] [PubMed]
[22] Raimondi, L., De Luca, A., Gallo, A., Costa, V., Russelli, G., Cuscino, N., et al. (2019) Osteosarcoma Cell-Derived Exosomes Affect Tumor Microenvironment by Specific Packaging of MicroRNAs. Carcinogenesis, 41, 666-677. [Google Scholar] [CrossRef] [PubMed]
[23] Wu, X., Zhou, H., Yue, B., Li, M., Liu, F., Qiu, C., et al. (2017) Upregulation of MicroRNA-25-3p Inhibits Proliferation, Migration and Invasion of Osteosarcoma Cells in vitro by Directly Targeting SOX4. Molecular Medicine Reports, 16, 4293-4300. [Google Scholar] [CrossRef] [PubMed]
[24] 翁宗琴, 赵海龙. 外泌体miRNA参与肿瘤化疗耐药的机制[J]. 中国组织工程研究, 2025, 29(7): 1504-1511.
[25] Jiang, D., Wu, X., Sun, X., Tan, W., Dai, X., Xie, Y., et al. (2022) Bone Mesenchymal Stem Cell-Derived Exosomal MicroRNA-7-5p Inhibits Progression of Acute Myeloid Leukemia by Targeting OSBPL11. Journal of Nanobiotechnology, 20, Article No. 29. [Google Scholar] [CrossRef] [PubMed]
[26] Qin, F., Tang, H., Zhang, Y., Zhang, Z., Huang, P. and Zhu, J. (2019) Bone Marrow‐Derived Mesenchymal Stem Cell‐Derived Exosomal microRNA‐208a Promotes Osteosarcoma Cell Proliferation, Migration, and Invasion. Journal of Cellular Physiology, 235, 4734-4745. [Google Scholar] [CrossRef] [PubMed]
[27] Wei, F., Ma, C., Zhou, T., Dong, X., Luo, Q., Geng, L., et al. (2021) Correction to: Exosomes Derived from Gemcitabine Resistant Cells Transfer Malignant Phenotypic Traits via Delivery of MiRNA-222-3p. Molecular Cancer, 20, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[28] Ma, Y., Yuwen, D., Chen, J., Zheng, B., Gao, J., Fan, M., et al. (2019) Exosomal Transfer of Cisplatin-Induced MiR-425-3p Confers Cisplatin Resistance in NSCLC through Activating Autophagy. International Journal of Nanomedicine, 14, 8121-8132. [Google Scholar] [CrossRef] [PubMed]
[29] Torreggiani, E., Roncuzzi, L., Perut, F., Zini, N. and Baldini, N. (2016) Multimodal Transfer of MDR by Exosomes in Human Osteosarcoma. International Journal of Oncology, 49, 189-196. [Google Scholar] [CrossRef] [PubMed]
[30] Xu, J., Wang, Y., Zhang, S., Chen, Y., Gu, H., Dou, X., et al. (2017) Exosomes Containing Differential Expression of MicroRNA and mRNA in Osteosarcoma That Can Predict Response to Chemotherapy. Oncotarget, 8, 75968-75978. [Google Scholar] [CrossRef] [PubMed]
[31] Ye, Z., Zheng, Z. and Peng, L. (2020) MicroRNA Profiling of Serum Exosomes in Patients with Osteosarcoma by High-Throughput Sequencing. Journal of Investigative Medicine, 68, 893-901. [Google Scholar] [CrossRef] [PubMed]
[32] Xie, F., Zhou, X., Fang, M., Li, H., Su, P., Tu, Y., et al. (2019) Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy. Advanced Science, 6, Article 1901779. [Google Scholar] [CrossRef] [PubMed]
[33] 肖敏, 华东, 刘永萍. 肿瘤外泌体疫苗的研究进展[J/OL]. 现代肿瘤医学, 1-8.
http://kns.cnki.net/kcms/detail/61.1415.R.20241111.1605.010.html, 2024-11-23.
[34] Shimbo, K., Miyaki, S., Ishitobi, H., Kato, Y., Kubo, T., Shimose, S., et al. (2014) Exosome-Formed Synthetic MicroRNA-143 Is Transferred to Osteosarcoma Cells and Inhibits Their Migration. Biochemical and Biophysical Research Communications, 445, 381-387. [Google Scholar] [CrossRef] [PubMed]
[35] Vandewalle, V., Essaghir, A., Bollaert, E., Lenglez, S., Graux, C., Schoemans, H., et al. (2020) MiR‐15a‐5p and miR‐21‐5p Contribute to Chemoresistance in Cytogenetically Normal Acute Myeloid Leukaemia by Targeting PDCD4, ARL2 and BTG2. Journal of Cellular and Molecular Medicine, 25, 575-585. [Google Scholar] [CrossRef] [PubMed]

为你推荐